Nevada Medicaid and Nevada Check Up News (Third Quarter 2024 Provider Newsletter) [Read]

Attention Behavioral Health Providers: Monthly Behavioral Health Training Assistance (BHTA) Webinar Scheduled [See Web Announcement 2009]

Attention All Providers: Requirements on When to Use the National Provider Identifier (NPI) of an Ordering, Prescribing or Referring (OPR) Provider on Claims [Announcement 850]

If you are a Medicaid provider whose revalidation application has not been processed by your termination due date, you will be ineligible to provide services to any Nevada Medicaid or Nevada Check Up recipients, including both Fee-for-Service and Managed Care Organization (MCO) enrolled recipients. See Web Announcement 1265

Enrollment Termination Frequently Asked Questions (FAQs) [Review]

Notifications

NOTIFICATION: The following Nevada Medicaid Provider Web Portal services will be unavailable from 8 p.m. to midnight Pacific Time Sunday, November 24, 2024, for scheduled maintenance:
  • Secure Provider Web Portal (Electronic Verification System – EVS), which includes:
    • Recipient Eligibility
    • Provider Claim Appeals
    • Prior Authorization (PA) system
    • Claims Submission
  • Online Provider Enrollment (OPE)
  • Gabby®, which includes:
    • Customer Service Center (877) 638-3472
    • Automated Response System (ARS) (800) 942-6511
  • Real time CAQH/CORE EDI eligibility and claim verification
  • Provider PASRR

Unwinding COVID-19 Information

Known System Issues-Click HERE

Paper claims are no longer accepted by Nevada Medicaid. Please refer to Web Announcement 1733 and Web Announcement 1829 for additional information.

Top 10 Claim Denial Reasons and Resolutions/Workarounds for September 2024 Professional Claims. See Web Announcement 3465.

Top Enrollment Return Reasons and Resolutions for January 2024 Submissions. See Web Announcement 3350.

Top Prior Authorization Denial Reasons for the Second Quarter of 2024. See Web Announcement 3427.

Attention Providers Using the Authorization Criteria Function: Results that return prior authorization (PA) requirements are accurate. For results that return “There are no records found based on the search criteria,” there may be a PA requirement if limits have been exceeded. To verify PA requirements, please refer to the Medicaid Services Manual (MSM) Chapter for your service type at dhcfp.nv.gov and the Billing Guide for your provider type at www.medicaid.nv.gov.

Scheduled Site Maintenance

During the scheduled site maintenance window the Provider Web Portal will be unavailable. The table below shows the regularly scheduled maintenance window. All times will be in the Pacific time zone.

Monday - Friday
12:00AM - 12:30AM

Monday
8:00PM - 12:00AM

Notice Date Title
Nov. 2, 2012 For Review at December 20 Meeting: Dopamine Agonists
Nov. 2, 2012 For Review at December 20 Meeting: Inhaled Antimuscarinics
Nov. 2, 2012 For Review at December 20 Meeting: Pancreatic Enzymes
Nov. 2, 2012 For Review at December 20 Meeting: Topical Retinoids
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: ADHD Agents and Stimulants
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Anticonvulsants
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Atypical (Second-Generation) Antipsychotics
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: B2 Agonists Single-Entity Agents
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Cholesterol Absorption Inhibitors
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Erythropoiesis-Stimulating Agents
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Growth Hormone
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Hepatitis C Protease Inhibitors
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: HMG CoA Reductase Inhibitors
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Immunomodulators
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Inhaled Antimuscarinics
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Intranasal Corticosteroids
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Ophthalmic Antibiotics
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Oral Anticoagulants
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Oral Pulmonary Arterial Hypertension Agents
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Pancreatic Enzymes
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Proton Pump Inhibitors Single Entity Agents
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Sedative Hypnotics
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Third Generation Cephalosporins
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Topical Analgesics and Anesthetics
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Topical Benzoyl Peroxide and Antibiotic Combinations
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Tramadol and Related Products
Sept. 24, 2012 For Review at Third Quarter 2012 Meeting: Urinary Antispasmodics
June 26, 2012 For Review at June 28 Meeting: Neuropathic Pain Agents
June 26, 2012 For Review at June 28 Meeting: RxHIGHLIGHTS™ Vol. 5, Issue 6, 2012
June 18, 2012 For Review at June 28 Meeting: Anticonvulsants-Benzodiazepines
June 18, 2012 For Review at June 28 Meeting: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
June 18, 2012 For Review at June 28 Meeting: Gralise® (gabapentin)
June 18, 2012 For Review at June 28 Meeting: Inhaled Corticosteroid and Long-Acting β2-Agonist Combination Products
June 18, 2012 For Review at June 28 Meeting: Intranasal Corticosteroids
June 18, 2012 For Review at June 28 Meeting: Ophthalmic Prostaglandin Analogues
June 18, 2012 For Review at June 28 Meeting: Platelet Inhibitors
June 18, 2012 For Review at June 28 Meeting: Restless Legs Syndrome
June 18, 2012 For Review at June 28 Meeting: Scabicides and Pediculicides
June 18, 2012 For Review at June 28 Meeting: Topical Androgens
June 15, 2012 Agenda for June 28 Meeting
Mar. 21, 2012 For Review at March 22 Meeting: Amylinomimetics
Mar. 21, 2012 For Review at March 22 Meeting: Angiotensin II Receptor Blockers (ARBs)-Combination Products
Mar. 21, 2012 For Review at March 22 Meeting: Angiotensin II Receptor Blockers (ARBs)-Single Entity Products
Mar. 21, 2012 For Review at March 22 Meeting: Hepatitis C Protease Inhibitors
Mar. 21, 2012 For Review at March 22 Meeting: Incretin Mimetics
Mar. 21, 2012 For Review at March 22 Meeting: Inhaled Corticosteroid and Long-Acting β2-Agonist Combination Products
Mar. 21, 2012 For Review at March 22 Meeting: Ophthalmic Antibiotics
Mar. 21, 2012 For Review at March 22 Meeting: Ophthalmic Antihistamines
Mar. 21, 2012 For Review at March 22 Meeting: Ophthalmic Nonsteroidal Anti-Inflammatory Drugs
Mar. 21, 2012 For Review at March 22 Meeting: Oral Anticoagulants
Mar. 21, 2012 For Review at March 22 Meeting: Phosphodiesterase (PDE) 4 Inhibitors
Mar. 21, 2012 For Review at March 22 Meeting: Renin Inhibitors and Combination Products
Feb. 17, 2012 Agenda for March 22 Meeting

Return to Past Meeting Reports.